Chicago partner William Essig authored an analysis for Law360 titled “7th Cir. Focuses on Impossibility Preemption in Dolin v. GSK.”
The analysis examined the highly-anticipated 7th U.S. Circuit Court of Appeals ruling in Dolin v. GlaxoSmithKline LLC. The decision was notable because the court ruled that the plaintiff’s claims were preempted, but did not address whether an “innovator liability” claim could be pursued against a brand manufacturer under Illinois law. The plaintiff had only taken a generic paroxetine manufactured by another company and not GSK’s Paxil.
The article was first published in Drinker Biddle on Products.
Read "7th Cir. Focuses on Impossibility Preemption in Dolin v. GSK” in Law360.